Mitchell McLeod Pugh & Williams’s Vertex Pharmaceuticals VRTX Stock Holding History

Mitchell McLeod Pugh & Williams’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	2,037 +500	+33%	+$222K	0.12%	143
2026 Q1	$686K	Hold	1,537	–	–	0.1%	168
2025 Q4	$735K	Buy	1,537 +800	+109%	+$345K	0.1%	161
2025 Q3	$311K	Sell	737 -5	-0.7%	-$2.09K	0.05%	224
2025 Q2	$330K	Buy	742 +230	+45%	+$106K	0.06%	216
2025 Q1	$248K	Buy	512 +5	+1%	+$2.33K	0.05%	238
2024 Q4	$204K	Buy	+507	New	+$235K	0.04%	251

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mitchell McLeod Pugh & Williams's VRTX Position: Q2 2026 in Review

Mitchell McLeod Pugh & Williams increased its Vertex Pharmaceuticals (VRTX) stake by 33% in Q2 2026, buying an estimated $222K and bringing the position to 2,037 shares worth $1.01M. The position accounts for 0.12% of the portfolio, ranked #143.

Mitchell McLeod Pugh & Williams first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Mitchell McLeod Pugh & Williams held 2,037 shares of Vertex Pharmaceuticals worth $1.01M as of Q2 2026.
Mitchell McLeod Pugh & Williams bought 500 Vertex Pharmaceuticals shares in Q2 2026, an estimated $222K.
Vertex Pharmaceuticals made up 0.12% of Mitchell McLeod Pugh & Williams's portfolio in Q2 2026, its #143 holding.
Mitchell McLeod Pugh & Williams first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mitchell McLeod Pugh & Williams's 13F filing for Q2 2026, filed 11 Aug 2026.